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FOR THB RAAMI Sru~v INV~S,,<~A~OHS** 
clot disoIYoM With rIsloralio” Of infarct-related anrr, bbvd 
Row h the Okly mrrhsnisa km the improwd propnaxis and 
mortality reduction spe,, aNor thrombolytic therapy of acute 
myocardii infarction. A pilot study has rug&d that 100 ox of 
reambinan, tissue~lyp plamdnogon activator (r&PA) infused 
over 90 min may lead 10 higher patency rates than ,he cuwen, 
standard of 100 mg owl 3 h. I” ,tlis rn”,,i..“,Ol, randomized. 
opa label trial, 281 patients with acute myocardial infarctim 
received IOU ~g of rt.PA according to either the standard 3.h 
infusion regimen (an inilinl ltbmg bolun followed by W mg for the 
Is1 h. then 20 mail, for 2 h) or an accelerated 9Q.min regtmen 
aspirin during and tier ti-PA infusion. 
Al 60 win altar initiation of the r&PA inlusioo, the obwwd 
angiograpbic patency m,es were 76% (95% contidence iotwats 
65% ,o 84%) in ,tw accetlra,ed regtman gmup and 61% in ,I,( 
Reperfusion of the infarct-related coronary artery is the most 
likely mechanism of ,mproved prognosis and monality re- 
duction seen wilh thmmbolytic agents in acute myocardial 
infarction (t-7). Because earlier therapy has been shown to 
provide additional clinical benefits over later therapy. the 
goal of thrombolysis in myocardia! inbrclion ir ,o ertablish 
repelfusion in the infarct-related ar,erjj as quickly as possi- 
ble (4X.-14). 
The current standard regimen of the commercially avail- 
able recombinant tissue-type ptasmmogen activator IAI- 
---.- 
predict di8’rrent wogoows. Larger trials will determiw whether 
ibueasing the Irequency and tpeed ol rrprfusion wilt lead to 
improved prqnods a&r my&tat inlarcficw. 
(, Ain coil Cvdi0, :992;20:17-23) 
teplase. recombinant; rt-PA) is IW mg infused intravenously 
o&r 3 h. This dosing regtmen has a demonsrrared parency 
ra,e cf aoomximalety 25% a, 30 min. 55% a, 60 min and 70% 
at 90 mC(15-18). S&eral noncompara,ive trials (15.16.19) 
and a smgle comparative sludy (18) have suggested that 
alternative regimens that deliver more n-PA during ,he 
initisl ho ,o Xl min of therapy (an accelerated or “front- 
loaded” regimen) lead to increases in angiognphic patency 
rates a, 60and!Xt min. In apilot study by Neuhauset al. (I’:;. 
74 patients with xute myocardial infarction received IOG mg 
of rt-PA over 90 min. Angiogrdphy demonstrated patency 
rates of 74% at 60 min and 91% at 90 min with this 
front-loaded regimen. 
Although the colleclive resulls of these qludies suggest 
the potenual advantages of ar. acz!c~atcd z-P.4 regimen. 
controlled. randomixd. comparative data are needed Lo 
confirm ,he observed incrcasa in efficacy and to ewluate 
the safety profile of the newer regimen (20.21). Tbis study 
was underiaken to investigate the bypothesis lb?1 a front- 
losded IOBmgdoae of &PA would be associated with higher 
angiographic patency rates than would the standard dew. 
The objective of this multiccnter. open label, randomized 
clmical trial was to evaluate Ihe angiagraphic patency rates 
60 and 90 min after initiation of a IOO-mg dose of II-PA 
infused accordmg to either th? standard 3-h regimen or an 
accelerated, front-loaded 90.mio regimen. 
Methods 
Patient selection. Twenty-three centers participated in 
this study from November 1. 19RB to March I, 199% Pal&s 
experiencing acute myocardml infarction and presenting to 
one of the participating investigation sites were evaluated for 
inclusion in this study. All participating centers had individ- 
ual Institutional Review Board approval and all enrolled 
patients provided informed written consent before participa- 
tion. 
The mclusion criteria were chest pain that was consistent 
with coronary ischemia, lasted 230 min and was unrespon- 
sive to standard nitroglycerin therapy; chest pain duration 
<6 h before tream~ent. and eleclrocardiomsohic (ECGI 
evidence of infarc’ion with at least I-mm STae&~ent clew 
tion in at lea<! !?“c of three inferior leads 111. III or aVFI and 
at least wo contiguous precordial leads (V, lo ‘f6j or lateral 
leads I and aVL. Men and postmenopausal women <76 
years old I‘:: cligiLle ii ibt, tielgnsd : 1;5 kg and were able 
to Liidc,,go iviuw, znglop,dpii) .~;;biii 9tl min of initiation 
of the rt-PA infusion. 
Exclruion wiwriu *wre known pregnancy; any history of 
cerebrovascular accident or disease: uncontrolled hypellen- 
uon (blood pressure ,180 mm Hg systolic or > I IO mm Hg 
diastolic). any bleeding disorder, surgery; trauma (including 
protringcd cardiopulmonary resuscitation) or severe bleeding 
within IO days; previous coronary artery bypass surgery; 
other serious illness or current oral anticoa?&u therapy. 
Administration of rt.PA. Treatment allocations were 
based on a randomlv aenerated list of numbers. Each oatient 
cnrollcd in ihir op&-label study rccewed IW mg oi n-PA 
(Activase brand of Alteplase. recombinant provided bv 
Gencntcch). After randa&ation each patieniwas treated 
according to one of the following administration protocols: 
1) a 3-h controlled infusion with 60 mg during the 1st h 
(including a IO-mg bolus). 20 mg during the 2nd h and 20 mg 
during the 3rd h (IS.‘?): or 2) a 90.min controlled infusion 
with 85 mg during the tst 30 min (including a 15 mg bolus) 
and 35 mg over the next h (19). Figure I shows the cumuI~- 
live dew over time of n-PA administration in each of the 
treatment groups. 
A SJHM-U irmavenous bolus of heparin was administered 
to all oatients within 90 min of initiation of n-PA theraw and 
was &iowed by B continuous infusmn of I.wO U/h’ ior at 
least 24 h. The hepatin dose was titrated to maintain the 
panial*‘lromboplastin lime at 1.5 toltimesthe control level. 
All patients received 80 mg of oral aspirin before the II-PA 
infusion and 80 mgiday while receivmg heparin. The aspirin 
dose was increased to 325 mgiday after heparin administm- 
tion and was canticued at least until discharge. 
Figure 1. Cumulalive dose of recombinant tissue-type plasminogcn 
activator @t-PA) administered over time in each of the treatment 
grwps. 
Angiograpbic cvaluatlon. The study protocol called for 
angio&hif assessment of the infarct-r&ted coronary ar- 
tery at 60 and Xt min after initiation of rt-PA theraov. 
S&dardized orthogonal views of the infarct-related art&y 
were recorded. Contrast left ventriculocraohv w.a oer- 
formed with use of standardized project& aibprocedires 
at the time of initial coronary arteriography. Meibanicat 
isterverdion, such as angioplasty or bypass grafting, was not 
permitted before completion of the 90-min angiogram but 
WE subsequently performed at the discretion of the inves- 
tigator. 
Patency of the infara-related artery was assessed at each 
clinical site according to the ‘Thrombolysis in Myocardial 
Infarction (TIMI) Row grade classification: grade 0 = no 
perfusion beyond the point of occlusion; grade I = penetra- 
tion of contrast material past the area of obstruction with 
incomplete opacitication of the distal coronary bed; grade 2 
= complete pafusion of the distal bed at a slower rate than 
that of an uninvolved coronary artery and grade 3 = com- 
plete perfusion at a rate comparable to that of an uninvolved 
artery (2). 
Angiographic films and index ECGs were then forwarded 
to the Angiogmphic Core Laboratory at the Momefiore 
Medical Center. Albert Einstein College of Medicine in New 
York, New York. a center wi!h extensive experience in 
adographic interpretation as a TIM1 study site since 1963. 
The core labor&y protocol called for con~enws reading of 
films by two senior angiographers who had no knowledge of 
patient characteristics and treatment assignments. Any dis- 
crepancy between study site and core laboratory interprcta- 
fions was resolved b consensus. Copies ofCore Laboratory 
case report forms were sent directly to a Data Verification 
Center zit M~iw Medscal Center. Portland, Matne for inde- 
pendent tabulation and auditing of angiographic study cnd- 
points. 
Study end paints. The primary end point of thic study was 
the comparative angiographic pa:ency rates 90 min after 
initiation of the e-PA infusion. The secondary end point ulas 
the comparative angiographic patency rates at the time of 
initial angiography 60 min after mltiatton of n-PA therapy. 
Information was also collected on the patients’ clmw~i 
course during the hospital stay. all bleeding events and lhe 
:f?xt 31‘1.P” t+-.py 0’1 fibrinogen levels. 
Statistical consid&dio~. Aniographrc sta!os was de- 
fined for statistical purposes es “patent” (that is. TIM1 grade 
2 or 3) or “occluded” (TIM1 grade 0 or IL The sample size 
provided 80% power to detect a 15% (absolutel diflerence in 
angiographic patency at either 60 or 90 min (p = 0.O.V. 
Angiograms performed 66 ? I5 row after initiation of n-PA 
therapy were evaluated as 60.min aogiogramr and Ihow 
performed 90 * I5 min after n-PA initianon were evaluated 
as 90.min angiograms. Clinical course and bleeding events 
were tabulated according to treabnent groups. A t test was 
used to cornowe mean numeric data and a chi-sQuare test 
was used to’evaluate ordinal dam. Data are expressed as 
mean value + SD. Percentages are followed by their 95% 
confidence intervals (Cl). 
Results 
Study sample (Table IJ. A totai of 281 patients were 
enrolled in this stud; from November 1988 to March 199u. 
There were no statislically significant differences between 
the two groups in terms of demographic and baseline char- 
acteristics, including infarct location. Enzymatic confirma- 
tion of infarction occurred in 98% of both gaups. Compli- 
ance with study drug regimens was also similar in both 
randomized groups: I@0 mg of U-PA was received as pa 
protocol by 95% of patients in the standard dear group and 
by 98% of those in the icccierdted dose group: 89% of 
patients received heparin as per pmtoal in each group and 
88% received aspirin as per protocol in each group. 
Thirty-one patients were not included in iht ;:.&nphlc 
analysis (I5 m the standard dose group and 16 in the 
accelerated ose group): 26 patients were excluded because 
ofexccssive delays in performing angiogmphy and 5 because 
of misvng anglographic data. 
Angiographic oralwtion. Evaluable 60.min qiographic 
data were available from 173 patients. The mean time to 
angiagraphy wa< 62 f I min in rhe standard ose group and 
61 i 5 I&B ;n the accelerated ose group (Fig. 2). Pat. ncy of 
the infarct-related arierv was observed at 60 min in S4 of 86 
patients (63%;95% CI 2 52% to 73%) in the standard dose 
PIOUD and 66 of 87 uatienh (76% 95% CI = 65% to 84%) in 
The keleratcd ddse group (p = 0.03). Comparison of 
dxqraphic and baseline characteristics, including infarct 
location and time since onset. revealed no significant differ- 
ences between patients who underwent both 60-min and 
90.min angiography as compared with those undergoing only 
9&min angiogmphy. 
Ninety-minute angiographic patency data were available 
from 250 patients. The mean time to angiography was 90 ? 
3 and 91 2 4 min. respectively, for the standard and 
accelerated ose groups. At 90 min. patency was observed in 
94 of 122 patients (77%95% Cl = 68% to 84%) in the 
standard dose group and 101 of I28 patients (81%: 95% Ci = 
73% to 87%) in the accelerated ose group (p = 0.21). The 
mean global ejection fraction measured at line nf initial 
cardiac catheterization was 54 r 12% in the standard dose 
group and 56 f 12% in the accelerated ose group (p = NSJ. 
Clinical course (Tables 2 ZL 3’. !o this tria! designed tu 
evaluate angiographic end points, review of prospectively 
- 
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defined myocardjal infarction-relared c!inicat cven!s b;’ ran- 
domized treatment showed no difl‘crence br~wecn the 
groups. Review of clinical events by Yn-min angiographic 
status revealed congestive heart failure in 17 of S2 133%; 95% 
Cl = 21% to 48%) patients with an occluded inbrct-related 
artery as compared with 27 of 198 (146:‘)5% CI = 9% to 
19%) patients with a patent artery (p = 0.003). Morlalily in 
these two groups was 8% (95% CI = 2% II) 20%) and 5% 
(95% C1 = 3% co 9%), respectively (p = 0.50). 
In pat&is wifh data a~wilable from b&h 60. und 90.rrrk 
ongiograpky, recurrent ischemia occurred in 6of21 patients 
(29%; 95% CI = 12% to 54%) who had delayed reperfusion: 
lhat is, an infarct-related arrery was occluded at 60 min but 
patent at 90 min. as compared with 17 of 115 patients 
(15%; 95% Cl = 9% to 23%) who had early reperfusion; that 
is, an infarct-related artery was patenl at both 60 and 90 min. 
Table 3. Signihcani Bleeding Complicarionr 
Standard Accelerated 
Dose (%I Dose 1%) 
(n = 1381 I” = 143, 
11.6 9.8 
0.1 0.0 
0.1 ?.I 
1.4 0.7 
0.7 cl.7 
22 : .4 
14 “0 
4.3 38 
Of the 21 parienls who had delayed rqwfusion. 13 had TIMI 
grade 2 (62%) and 8 had grade 3 (38%) perfusion at 90 min, 
whereas of those with early reperfusion, 21 of 115 had TIMI 
grade 2 (18%) and 94 had grade 3 (82%) pcrfnsion at 90 min. 
Si~n$cunf bleeding complicnkms were rare and nc- 
curred with equal frequency in both treatment groups (Table 
3). Two hnracranial hemorrhages occurred in this trial, both 
in the standard dose group. One patient with abaseline blood 
prcswe oi 1801110 mm Hg but no other risk factors sus- 
lnined a small. focal cerebral hemorrhage and was dis- 
chaKged with no aeurologic abnormality except a visual held 
deficit. The other patient developed a stroke syndrome after 
coronary artery bypass surgery and mitra! valve repair for 
papillary muscle rupture. Computed tomographic scannmg 
mitially revealed cerebral infarction, but sobsequenuy 
showed hemorrhage into the infarcted area. The patient died 
on day 7 after thrombolysis. 
Thejhrinogen level wns reduced by 33.3% during freaf- 
menu ~i~fr rhe aecete~l~ed regimen from a mean fibrinogen 
level of 329.5 mgldl at baseline lo 197.2 mg/dl 4 h after 
initiation of rt-PA compared with a 25.6% red&ion with the 
standard dose from 313.7 mg/dl to 219.5 mgidl. The mean 
fibrinoxen level OT the accelerated dose WJUD was sienifi- 
cantlyiower than that of the sIandsrd dos;gro& at 4 h& = 
0.02). 
Discussion 
Increased eficacy through accelerated dosing. The results 
of the RAAMI study indicate that an accelerated r&PA 
regimen uf 100 mg infused over 90 min causes earlier 
reperfusion than the same dose delivered over 3 h, as 
reflected in a significantly higher patency rate, 76% versus 
63%. respectively, at Kl min. The Wmin patency rate of 
81% for the accelerated regimen was not significantly differ- 
ent from the 77% rate observed whh the standard regimen. 
Serial angiographic injections into the infarct-related artery 
may have contributed to the observed patency rates. Be- 
cause the prolocal specihed the sequence of injections and 
Ihe Crst injection at any time point was used for protocol end 
points. any efiect would be equal in both randomized groups. 
When the data from the RAAMI study were pooled whh 
those of other similar trials (l5.l6,18,19) of standard and 
accelerated II-PA regimens that evaluated serial angio- 
graphic patency rates according to the TIM1 flow grade 
criteria, the following results were oh:ained (Fig. 3 and 4). 
Parency at 60 min with accelere;d r?-PA dosing was ub- 
served in 213 of301 patients(II%;95%Cl = 65%Lo76%)as 
compared with 181 of 328 palients treated with the standard 
regimen (55%;95% Cl = 50% to 61%) (p < O.iKlS). Palency 
at 9G min was observed in 286 of 345 paticms treated with Ihe 
accelerated rt-PA ree,mcn (83%: 95% CI = 78% to 87%1 as 
compared with 263 of 363 patients treated with the standard 
regimen (72%; 95% Cl = 68% to 77%) (p < O&IS). 
This analysis supports the conclusion that an increased 
amounl of rt-PA delivered during the Is.1 90 min of therapy 
leads to increasea patency a1 60 and 90 min. These studies 
were designed to measure standardized angingraphic end 
points, so comparative information an clinical outcomes 
(such as ventricular function, mortality or safety) is not 
available. However, because angiographic patency after 
thrombolytic therapy is linked to clinical Outcome. it can be 
anticlparel fhat increased thrombolytic e9icacy will trans- 
late into improved pdient prognosis. This hypothesis awaits 
confirmation from a larger. zndomized trial. 
hpliestioosfw impruvd iniid efficacy. In the RAAMt 
study, accelerated dosing was accompanied by a significant 
increase in fibrinogen degradation. This confirms an obser- 
vation from the other randomized dosing trial (IS), even 
though a higher total dose was nsed in that trial. Because 
fibrintoeen) dearadation oroducts are potent inhibitors of 
tbroibin, ~ec&nr w&ion and r&rent ischemia may 
be decreased after accelerated dosing (21.2+25;. This is 
especially important in ii& of recent data describing the 
importance of the antithmmbin effect of heparin after SW 
cessful thrombolvsis with SPA 126.27). 
linked to a modest increase in bleeding compdcatians 
(15,24,X). Furthermore. higher doses of rt-PA have been 
associated with an increase in bleeding complications 
(15. IR). bur whether this is due to an increase in total dose or 
M increase in the rate of administration is unknown. The 
precise relation hehveen the increased e0icacy observed 
with accelerated dosing and the clinical course tier rt-PA 
therapy awaits evaluation in additional trials. 
In the RAAMl study, earlier angiowphic patency was 
not aseociared with an increase in early recurrent ixhemia 
or reocclusion. but the small sample size iimits the power of 
these observations. Larger studies may dezzn& zbctbe: 
the shorter infusion duration and the increase in early 
patency will be accompanied by an ixrease in these events. 
The optimal dose of aspirin in combination with rt-PA and 
heptin is not known a& doses of SO !o 33 mgiday have 
been administered to patients in myocardiat iafarclion trials. 
The dose of aspirin in this trial (80 mg initially followed by 
SO mgi3ay) ws not associated with an unexpectedly low 
initial patency rate or with an unexpectedly high rate of 
clinical events that could be attributed to rcocclusion. 
Analysis of angiographic subs@. The observation in the 
RAAMl study of a higher incidence of congestive beti However, in&eased fibrin(ogen) degradation has been 
bilure in patients with persistent infarct-related mtery OC- 
clusiorr at 90 min. reaardless of treatment assienmer.1. illus- 
trates the benefits of early restoration of blood Row to 
ischemic myocardium, now well documented in many other 
stodies (I ,3-6,14). 
Uf additional interest ~b the obscrvaton of a diBererce 
in recurrent &hernia rates among patients wth )I patent 
infarct-related artery ai 90 min depending on 60.min arterial 
pateoey status. To our knuwledge. this is the first report of 
thts observation. Further analysis of pBtients with a 
“tntent” infarct-related anew at 90 mitt (such as TIM1 tlow 
g&e 2 or 3) revealed a high& proportion of TlMl grade 2 
ROW (62%) in patients with delayed reoerfusion (occluded at 
(10 min but paient at 90 min), whereas those with early 
raperfusion (patent at both 60 and 90 min) had a higher 
orcaortion of TIMI grade 3 flow (82%). Reduced TIM1 Raw 
iraie at 90 min has already been identified as a predictor of 
reocdusion, and reocclusion curies a risk of increased 
morbidity and mortalily (7,281. ‘This observation suggests 
that speed of reperfusi& is linked to efficiency of repetfu- 
sionand thatmoreefficicntthrombolvsis (that is.TIMI uade 
3 flow) ha incremental advantages Thts further sug&ts 
that pursuit of earlier and more efficient reperfusion through 
mechanical or adjunctive pharmacolo@c methods. or both, 
may be warranted. Additional studies may explore this 
hypothesis further. 
ConcluEions. The results of the randomized. comparative 
RAAMI study agree with the results of other trials demon- 
slrating that an accelerated regimen 0: 100 mg of n-P.4 
ix:cascs rhromhclgt~i eificacy as measwed by anglographic 
patency without an apparent change io safety profile. Fer- 
ther studies may evaluate whether this increw in efficacy 
produces addttional clinical benefits. 
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